ZO-1

By Targets:	Bacterial (1) Drug Metabolite (4) Endogenous Metabolite (4) iGluR (1) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) nAChR (4) NF-κB (1) p38 MAPK (1) Phosphatase (1) Reference Standards (1) SARS-CoV (1) Small Interfering RNA (siRNA) (3) β-catenin (4)
By Research Areas:	Cardiovascular Disease (4) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (5)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6612B

Glucuronic acid sodium	Bacterial	Inflammation/Immunology
Glucuronic acid sodium is a polysaccharide that exhibits anti-inflammatory activity, supporting the healing of ulcerative colitis. Glucuronic acid sodium also enhances the intestinal barrier by upregulating tight junction proteins like ZO-1 and Occludin. Furthermore, Glucuronic acid sodium plays a role in modulating gut microbiota by increasing beneficial bacterial populations while suppressing harmful ones.

HY-W002112

(±)-Nornicotine Nornicotine	Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and *ZO-1, and induces F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

HY-W002112S

(±)-Nornicotine-d4	nAChR Isotope-Labeled Compounds Endogenous Metabolite Drug Metabolite β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and *ZO-1, and induces F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

HY-175460

SARS-CoV-2-IN-117	SARS-CoV	Infection
SARS-CoV-2-IN-117 (Compound C19) is a SARS-CoV-2 E protein inhibitor. SARS-CoV-2-IN-117 significantly inhibits SARS-CoV-2 E protein interaction with host ZO-1 PDZ2 domain. SARS-CoV-2-IN-117 has potent antiviral activity and significantly reduces viral replication. SARS-CoV-2-IN-117 can be used for COVID-19 research ^[1].

HY-N8563

Masticadienonic acid	p38 MAPK NF-κB Keap1-Nrf2	Inflammation/Immunology
Masticadienonic acid is an orally active and selective inhibitor of MAPK (p38, ERK, JNK) and NF-κB pathways and an agonist of the Nrf2 pathway. Masticadienonic acid reduces the release of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6, restores the expression of intestinal tight junction proteins (ZO-1, occludin), and modulates gut microbiota. Masticadienonic acid is promising for research of inflammatory bowel disease ^[1].

HY-W002112R

(±)-Nornicotine (Standard) Nornicotine (Standard)	Reference Standards Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and *ZO-1, and induces F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

HY-W002112S1

(±)-Nornicotine-d7	Isotope-Labeled Compounds Endogenous Metabolite Drug Metabolite nAChR β-catenin	Cardiovascular Disease Neurological Disease
(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and *ZO-1, and induces F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

HY-RS20347

Tjp1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tjp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tjp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tjp1 Mouse Pre-designed siRNA Set A Tjp1 Mouse Pre-designed siRNA Set A

HY-RS14553

TJP1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
TJP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TJP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

TJP1 Human Pre-designed siRNA Set A TJP1 Human Pre-designed siRNA Set A

HY-RS26856

Tjp1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Tjp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tjp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Tjp1 Rat Pre-designed siRNA Set A Tjp1 Rat Pre-designed siRNA Set A

HY-117772

FSC231	iGluR	Metabolic Disease Inflammation/Immunology
FSC231 is a PSD‐95/DLG/ZO‐1 (PDZ) domain inhibitor of *PICK1*. FSC231 has analgesic effects ^[1].

HY-120327

KY-226 2 Publications Verification	Phosphatase	Neurological Disease Metabolic Disease
KY-226 is a potent, selective, orally active and allosteric protein tyrosine phosphatase 1B (PTP1B) inhibitor with an IC₅₀ of 0.25 μM, and without PPARγ agonist activity. KY-226 exerts anti-diabetic and anti-obesity effects by enhancing insulin and leptin signaling, respectively. KY-226 also protects neurons from cerebral ischemic injury ^[1] .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W002112

(±)-Nornicotine Nornicotine	Structural Classification Alkaloids Pyrrole Alkaloids Neurological Disease Classification of Application Fields Source classification Pyridine Alkaloids Endogenous metabolite Disease Research Fields	Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and *ZO-1, and induces F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

HY-N8563

Masticadienonic acid	Triterpenes Structural Classification Terpenoids Source classification Pistacia terebinthus L. Plants Anacardiaceae	p38 MAPK NF-κB Keap1-Nrf2
Masticadienonic acid is an orally active and selective inhibitor of MAPK (p38, ERK, JNK) and NF-κB pathways and an agonist of the Nrf2 pathway. Masticadienonic acid reduces the release of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6, restores the expression of intestinal tight junction proteins (ZO-1, occludin), and modulates gut microbiota. Masticadienonic acid is promising for research of inflammatory bowel disease ^[1].

HY-W002112R

(±)-Nornicotine (Standard) Nornicotine (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Source classification Pyridine Alkaloids Endogenous metabolite	Reference Standards Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and *ZO-1, and induces F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

Cat. No.	Product Name	Chemical Structure

HY-W002112S

(±)-Nornicotine-d4
(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and *ZO-1, and induces F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

(±)-Nornicotine-d4

(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

HY-W002112S1

(±)-Nornicotine-d7
(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and *ZO-1, and induces F-actin* depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

(±)-Nornicotine-d7

(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia ^[1] .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83694

	ZO-1/TJP1 Antibody (YA3430) 1 Publications Verification ZO1_HUMAN; Tight junction protein ZO-1; TJP1; ZO1; Tight junction protein 1; ZOna occludens protein 1; ZOnula occludens protein 1; ZO1 tight junction protein;	WB, IHC-P, ICC/IF	Human, Mouse, Rat, Monkey
	ZO-1/TJP1 Antibody (YA3430) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ZO-1/TJP1.

HY-P86250

	ZO-1/TJP1 Antibody (YA5942)	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	ZO-1/TJP1 Antibody (YA5942) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to ZO-1/TJP1.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-RS20347

Tjp1 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Tjp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tjp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS14553

TJP1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
TJP1 Human Pre-designed siRNA Set A contains three designed siRNAs for TJP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

HY-RS26856

Tjp1 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Tjp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tjp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Antibodies

Oligonucleotides